<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168181</url>
  </required_header>
  <id_info>
    <org_study_id>HN-04-0010</org_study_id>
    <nct_id>NCT00168181</nct_id>
  </id_info>
  <brief_title>Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients</brief_title>
  <official_title>A Phase III Randomized Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CancerCare Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newfoundland Cancer Treatment &amp; Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Notre-dame Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <brief_summary>
    <textblock>
      This is a study to see whether the drug Salagen or salivary gland transfer is better for the
      prevention of dryness of the mouth in patients with head and neck cancer receiving radiation
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date>April 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy of prevention of XRT induced xerostomia using two different approaches: oral Pilocarpine versus submandibular salivary gland transfer protocol; To compare the rate and severity of XRT induced xerostomia using these two strategies</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of oral candidiasis, percutaneous endoscopic gastrostomy (PEG), and hospitalization during XRT</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Submandibular gland Transfer</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salagen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previously untreated and confirmed histological diagnosis of squamous cell/adenoid
             cystic carcinoma of the oropharynx, hypopharynx, larynx, and patients with unknown
             primary tumor with metastases to the neck nodes and squamous cell carcinoma of the
             skin of head and neck region with ipsilateral neck nodes (more than one node)
             metastases.

          2. Radiation volume to encompass &gt; or equal to 80% of major salivary glands (parotids and
             the non-transferred submandibular salivary gland) and have &gt; or equal to 50 Gys
             delivered to that volume via external beam.

          3. Karnofsky performance score &gt; or equal to 70

          4. Minimum age 18 years

          5. The patient must sign a study-specific informed consent prior to study entry

          6. Expected survival &gt; or equal to one year

        Exclusion Criteria:

          1. Carcinoma of nasopharynx, oral cavity, N3 disease, bilateral neck node involvement,
             pre-epiglottic space involvement, involvement of level 1 nodes on either side of the
             neck, and patients with post-operative recurrent disease.

          2. Salivary gland malignancy

          3. Salivary gland disease

          4. Use of anti-cholinergic drugs and tricyclic drugs

          5. Delay in XRT of more than 8 weeks following the curative surgery

          6. Pregnant or lactating females are not eligible. Patients of childbearing potential
             should agree to use an effective method of contraception

          7. Prior head and neck irradiation

          8. Recurrent disease

          9. Allergy to pilocarpine

         10. Patients with uncontrolled asthma, acute iritis, or narrow angle glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naresh Jha, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHS Cancer Control Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>April 15, 2011</last_update_submitted>
  <last_update_submitted_qc>April 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2011</last_update_posted>
  <keyword>salagen</keyword>
  <keyword>gland transfer</keyword>
  <keyword>randomized</keyword>
  <keyword>xerostomia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

